web viewtotal word count: address for c. orrespondence: ... sugiyama s, sugamura k, nozaki t, ohba...
TRANSCRIPT
Effect of coronary atherosclerotic burden and inducible myocardial ischemia on
circulating levels of high sensitivity cardiac troponin T (hs-cTnT) and N terminal
probrain natriuretic peptide (NT-proBNP) in patients with stable angina: results
from the EVINCI study.
Cardiac biomarkers and stable angina.
Chiara Caselli,a Concetta Prontera,b Rosetta Ragusa,c Riccardo Liga,d Michiel A. De
Graaf,e Valentina Lorenzoni,c Silvia Del Ry,a Daniele Rovai,a Daniela Giannessi,a
Oliver Gӓemperli,f Jeroen J. Bax,e Massimo Lombardi,b Rosa Sicari,a Jose’ Zamorano,g
Arthur J. Scholte, e Philipp A. Kaufmann,f Juhani Knuuti,h S Richard Underwood,i
Aldo Clerico, b,c Danilo Neglia, MD.a,b
a CNR, Institute of Clinical Physiology, Pisa, Italy;
b Fondazione Toscana G. Monasterio, Pisa, Italy;
c Scuola Superiore Sant’Anna, Pisa, Italy;
d Cardio-Thoracic and Vascular Department, University Hospital of Pisa, Pisa, Italy;
e Leiden University Medical Center, Leiden, The Netherlands;
f University Hospital Zurich, Zurich, Switzerland;
g University Hospital Clinico San Carlos, Madrid, Spain;
h University of Turku and Turku University Hospital, Turku, Finland;
i Imperial College London, United Kingdom
This work was supported by a grant from the European Union FP7-CP-FP506 2007
project (grant agreement no. 222915, EVINCI).
1
The authors declare that they have no relationships relevant to the contents of this
paper to disclose.
Total word count:
Address for correspondence: Chiara Caselli, PhD
CNR Institute of Clinical Physiology
Area della Ricerca – Via Moruzzi, 1 56100 Pisa
Fax: 39 050 3152166
Phone: 39 050 3152019
e-mail: [email protected]
2
Abstract
Background. Circulating levels of high sensitivity cardiac troponin T (hs-cTnT) and
N terminal probrain natriuretic peptide (NT-proBNP) are predictors of coronary artery
disease (CAD) and long term prognosis in patients with stable angina.
Purpose. The aim of this study was to evaluate the effect of coronary atherosclerotic
burden and inducible myocardial ischemia on cardiac release of hs-cTnT and NT-
proBNP in a contemporary European population of patients with suspected CAD.
Methods. Hs cTnT and NT-proBNP were measured in 378 patients (60.1 ±0.5 years,
229 males) with stable angina and unknown CAD enrolled in the Evaluation of
INtegrated Cardiac Imaging (EVINCI) study. All patients underwent stress imaging,
by myocardial perfusion or wall motion imaging, to detect inducible ischemia, and
coronary computed tomography angiography (CTA) to assess the presence of CAD
(>50% stenosis of at least one major coronary vessel). An individual CTA score,
expressing the coronary atherosclerotic burden, was calculated combining extent,
severity, composition, and location of plaques.
Results. In the whole population the median (IQR) value of plasma hs-cTnT was 6.17
(4.2-9.1) ng/L and of NT-proBNP was 61.66 (31.2-132.6) ng/L. In a multivariate
model, CTA score was an independent predictor of the plasma hs cTnT (coefficient
0.06, SE 0.02, p=0.0089), while ischemia was a predictors of NT-proBNP (coefficient
0.38, SE 0.12, p=0.0015). When patients were subdivided according to the
absence/presence of CAD and ischemia, hs-cTnT concentrations were significantly
increased in patients with CAD with or without inducible ischemia (p<0.005), while
only patients with CAD and ischemia showed significantly higher levels of NT-
proBNP compared with all the other groups (p<0.001).
3
Conclusions. In patients with stable angina, the presence and extent of CAD is related
with increased levels of hs-cTnT also in absence of ischemia. This suggest an
ischemia-independent mechanisms of hs cTnT release linked with coronary
atherosclerosis. NT-proBNP is a strong and independent predictor of obstructive CAD
causing myocardial ischemia, thus identifying those subject at high risk of future
events, probably requiring invasive procedure.
Keywords
hs cardiac Troponin T, NT-proBNP, stable angina, coronary artery disease,
atherosclerotic burden, myocardial ischemia, cardiac imaging
4
Introduction
The stable coronary artery disease (CAD) population represents a heterogeneous group
of patients for patho-physiologic substrate, clinical presentation and outcome (1).
These patients may have different morphology, severity and extent of coronary
atherosclerotic lesions and of inducible myocardial ischemia and these multiple
aspects may have independent prognostic value (2-3).
High-sensitivity cardiac troponins (hs-TnT) is commonly used in the diagnosis of
acute coronary syndromes (4-7). Recently, it has been shown that episodes of minute
troponin release, below the threshold for acute myocardial infarction, often occur in
patients with stable CAD and this has been demonstrated to predict all cause
mortality, cardiovascular mortality and heart failure (HF) (5-8). N-terminal pro brain
natriuretic peptide (NT-proBNP) is a powerful prognostic indicator in patients with
left ventricular (LV) dysfunction and HF. However, it is also a predictor of all cause
and cardiovascular mortality in patients with stable CAD without HF (9-11), Hence
both these biomarkers may be used as prognostic indicators in stable CAD (5-11).
The aim of this study was to evaluate the effect of coronary atherosclerotic burden,
assessed by CT angiography (CTA), or myocardial ischemia, assessed by stress
imaging, on cardiac release of hs-cTnT and N-terminal pro B-type natriuretic peptide
(NT-proBNP) in patients with stable CAD enrolled in the EValuation of INtegrated
Cardiac Imaging (EVINCI) (12). In the subgroup of EVINCI patients in whom
imaging fusion of CTA and myocardial perfusion imaging (MPI) was performed, the
combined effects of coronary atherosclerosis and downstream inducible ischemia on
circulating biomarkers was also evaluated.
5
Materials and Methods
Population, diagnostic protocol and study design
Patients with stable chest pain or equivalent symptoms and intermediate probability of CAD were studied. These patients were enrolled at 14
European centres in the EValuation of INtegrated Cardiac Imaging for the detection and characterization of ischemic heart disease (EVINCI) study
(12). Patients with acute coronary syndrome, known CAD, left ventricular ejection fraction < 35%, significant heart valve disease, cardiomyopathy
or contraindications to stress imaging were excluded. According to the EVINCI protocol, each patient underwent CTA, stress imaging (by MPI or
WMI) and - if at least one non invasive tests was positive - invasive coronary angiography and measurement of FFR when indicated (12). Ethical
approval was provided by each participating centre and all subjects provided written informed consent.
The patients whose CTA images and plasma samples were available for core laboratory analyses were included in this study. Patients with also
available MPI studies by SPECT or PET were included in a sub-analysis. Image fusion of MPI with CCTA datasets and hybrid analysis were
performed by a dedicated core laboratory.
Blood collection and analysis
Blood samples were collected before non-invasive imaging in tubes with EDTA and then locally separated by centrifugation for 15 min at 1000 ×g.
Plasma samples were provisionally stored in a local refrigerator at - 80°C and shipped to the bio-humoral core laboratory (CNR-Institute of Clinical
Physiology, Pisa, Italy) for the final cryo-conservation in the EVINCI biological bank (13-14). Analyses of hs-cTnT and NT-proBNP were
performed at the Laboratory of Fondazione Toscana G. Monasterio (Pisa, Italy) using standard clinical laboratory procedures on automatic analyzers,
according to the recommendations made by the manufacturer (Roche Diagnostics International Ltd, Switzerland). Plasma concentrations of cTnT
were measured using the hs-cTnT method on COBAS E411 with Elecsys Troponin T hs STAT by Roche Diagnostics, as previously described in
detail (15 ).
Measurement of NT pro-BNP was performed using the electrochemical luminescence immunoassay Elecsys proBNP II by Roche Diagnostics using
monoclonal antibodies, as previously described in detail (16).
In order to complete the clinical/biohumoral profile of study patients, additional traditional biomarkers were measured using standard methods (13-
14).
Image acquisition
6
Image acquisition protocols were agreed on for each technique covering patient preparation, cardiovascular stress, administration of
radiopharmaceutical or contrast medium, image acquisition and quality control. These procedures were based on best available clinical practice.
Image analysis and reporting was performed at specific core laboratories dedicated to each technique by experienced observers blinded to clinical
history and other imaging findings (12).
Coronary CTA analysis and CTA risk score
The coronary CTAs were analyzed in a core laboratory (Leiden University Medical Center, Leiden, The Netherlands) by consensus of experienced
observers blinded to any other clinical data or imaging test. First, each segment of the AHA 17-segment model was assessed for interpretability.
Segments were defined as uninterpretable in case of severe motion artefacts or low contrast resolution. Additionally, segments with a diameter ≤ 1.5
mm were excluded. Interpretable segments were evaluated for stenosis, which was then stratified into four different categories: normal if no
atherosclerosis was present, non-obstructive if the stenosis severity was <50%, obstructive for lesions with 50-70% stenosis of the coronary artery
lumen. If plaque was present, plaque composition was visually determined (calcified, mixed, non-calcified). One type of plaque composition was
assigned per segment.
In 297/376 patients, CT acquisitions for coronary artery calcium were available and the Agatston CAC score was computed according to standard
methods.
A previously established CTA risk score was derived in each patient integrating all data on the location, severity, and composition of CAD (17). In
brief, the score consists of three weight factors for each segment of the coronary tree. A stenosis severity weight factor, a stenosis location weight
factor, and a weight factor for plaque composition. All three weight factors are multiplied to calculate the segment score. The risk score for each
patient is calculated by adding all segment scores.
Non invasive stress imaging analysis
MPI and WMI were defined as abnormal if there was either an inducible perfusion abnormality or myocardial scarring. Perfusion in each of 17
segments was classified as 0 = normal, 1 = mild reduction, 2 = moderate reduction, 3 = severe reduction or 4 = absent perfusion and the segmental
scores were summed for the stress and rest images. For MPI, an inducible perfusion abnormality was defined as a summed segmental difference score
between stress and rest images ≥ 2, either from a score ≥ 1 in at least two contiguous segments or ≥ 2 in at least one segment. Scarring was defined
similarly from the summed segmental rest score. For WMI, segmental myocardial wall motion was scored at rest and during stress as normal (0),
7
hypokinetic (1), akinetic (2) or dyskinetic (3). Inducible ischaemia was defined as an increase in segmental wall motion score ≥ 1 from rest to stress
in at least two contiguous segments. Scarring was defined similarly from the resting wall motion score.
Hybrid imaging
In the subgroup of 195 patients submitted to MPI by PET or SPECT with an excellent image quality, a hybrid imaging study was performed.
Individual datasets from MPI and CTA were transferred to a dedicated hybrid core laboratory blinded to clinical history and imaging findings
(University Hospital Zurich, Switzerland). Image fusion of MPI and CCTA datasets was performed on a dedicated workstation (Advantage
Workstation 4.4, GE Healthcare) using the CardIQ Fusion software package (GE Healthcare) as previously described (18). In case of H215O-PET
images, parametric myocardial blood flow (MBF) datasets, showing MBF on a segmental level, were first generated and quantitative analysis was
performed using an in-house developed software, PMOD 3.6 software package (PMOD Technologies Ltd., Zurich, Switzerland). Then hybrid
analysis was performed using an optimized alignment tool that allows projection of the MPI image on the left ventricular epicardial surface obtained
from the CTA. The 3D volume rendered fusion images allow a panoramic view of the coronary artery tree projected onto the left ventricular
myocardial perfusion territories. Images can be displayed in freely selectable angles and displayed in standard anterior, posterior, lateral, and apical
view for standardized documentation and reporting. In all patients, the image fusion procedure (including image generation and reading) was
performed.
A patient’s CTA was considered abnormal if at least one coronary artery had a diameter stenosis >50%. According to an intention-to-diagnose
strategy, any non-diagnostic segment was considered abnormal. Significant left main stem stenosis were assigned to both left anterior descending
(LAD) and left circumflex (LCX) coronary arteries. A reversible perfusion defect (ischemia) was defined as a SDS ≥2, either from a score ≥ 1 in at
least two contiguous segments or ≥ 2 in at least one segment. Myocardial scar was defined similarly as a SRS ≥2. Each perfusion defect was assigned
to one or more coronary territories according to the standardized myocardial segmentation model proposed by Cerqueria et al. (19).
All hybrid MPI/CCTA images were analysed with regard to the presence of hemodynamically significant coronary lesions. Specifically, each
abnormal myocardial segment was assigned to the pertinent vascular territory by spatial coregistration according to patients’ individual coronary
anatomy. A matched hybrid imaging finding was defined as a perfusion defect in a territory subtended by a stenotic coronary artery on CCTA. All
other combinations of pathologic findings were classified as unmatched.
Statistical analysis
8
Categorical variables are presented as numbers (percentage), continuous variables as mean ± SD or median [25-75 percentile] depending on their
distribution.
Differences in continuous variables between two groups were tested using Student’s t test or Mann-Whitney test. Comparisons among groups were
performed using ANOVA analysis and Kruskall-Wallis test, Bonferroni test or Mann-Whitney test using Bonferroni correction for P-value were used
for post-hoc comparisons. Pearson’s chi-squared test was used to compare categorical data.
Univariate and multivariate linear regression were used to estimate the effect of clinical variables as well as imaging results on hs-cTnT and NT-
proBNP plasma levels. the. All models were developed considering variables with P value < 0.1 at univariate analysis and then using backward and
forward stepwise selections to build up the final models. The logarithmic transformation of continuous variables was used in linear regression
analysis.
All analyses were performed using StataCorp. 2007. Stata Statistical Software:
Release 10. College Station, TX: StataCorp LP. A 2-sided value of P <0.05 was
considered statistically significant.
Results
Baseline clinical characteristics of study population
In the whole population the median (interquartile range) value of plasma hs-cTnT was 6.17 (4.16-9.09) ng/L and of NT-proBNP was 61.66 (31.19-
132.60) ng/L.
Only 34 (9%) and 77 (20%) of patients had plasma levels of hs-cTnT and of NT-proBNP exceeding the upper limits of the normality ranges (14
pg/mL and 157 ng/L, respectively). The median values were used as cut-off points to divide patients into groups with low (< median) or high (≥
median) concentrations of hs-cTnT and NT-proBNP. Baseline characteristics of the patients are compared between groups in Table 1. Patients with
high levels of hs-cTnT were older and had higher frequency of male sex, diabetes, hypertension, anti-diabetic and anti-hypertensive treatments than
patients with low levels of hs-cTnT. Patients with high levels of NT-proBNP were also older than patients with low levels of NT-proBNP but showed
a lower frequency of male sex and diabetes and a lower LV ejection fraction. The metabolic and inflammatory profile was altered in patients with
high levels of hs-cTnT but not in those with high NT-proBNP levels.
Coronary atherosclerosis and inducible myocardial ischemia
9
Results from CTA (coronary anatomy, plaque characterization and risk scores) and stress imaging (inducible myocardial ischemia) are compared
between groups of patients with high or low hs-cTnT or NT-proBNP in Table 2.
Biomarker levels were associated with the severity and the extent of CAD. Patients with high hs-cTnT as well as patients with high NT-proBNP
showed a higher frequency of obstructive coronary lesions as compared with patients with low hs-cTnT and NT-proBNP who showed a higher
frequency of normal coronary arteries. Figure 1 illustrates the increase of hs-cTnT and NT-proBNP plasma levels according to the presence of non
obstructive or obstructive coronary lesions (Figure 1A) or with the number of any coronary lesion (either obstructive or non obstructive) (Figure 1B).
The two biomarkers were differently associated with plaque types. Patients with high hs-cTnT, but not patients with high NT-proBNP, showed more
frequently calcified or mixed plaques than patients with low hs-cTnT and had a higher number of mixed plaques. CTA risk score was significantly
higher in patients with high hs-cTnT or high NT-proBNP while CAC score was significantly higher only in patients with high hs-cTnT (Table 2).
Both patients with high hs-cTnT and high NT-proBNP had higher frequency and extent of inducible ischemia (Table 2) .
Integrated effects of coronary atherosclerotic burden and inducible ischemia on circulating hs-cTnT and NT-proBNP levels
Multiple linear regression model was used to identify the independent predictors of elevated levels of hs-cTnT and NT-proBNP (Table 3). Age, male
sex and CTA risk score were independent predictors of increased hs-cTnT levels. Age, female sex, lower LVEF and presence of ischemia were
independent predictors of increased NT-proBNP levels.
Patients were subdivided in groups according to the absence or the presence of coronary atherosclerosis (CAD) and ischemia, either alone or
combined. Patients with CAD with/without ischemia showed significantly higher levels of hs-cTnT than patients without CAD, while only patients
with CAD plus ischemia had significantly higher levels of NT-proBNP as compared with all the other groups (Figure 2A).
Similar results were obtained by hybrid imaging analysis. Patients with a perfusion defect in a territory subtended by a stenotic coronary artery on
CTA (macthed) were compared with patients with all other combinations of pathologic findings (unmatched) and with normals. As compared with
normals, NT-proBNP levels were significantly increased only in patients with matched findings while hs-cTnT levels were significantly elevated in
both patients with matched and mismatched findings. (Figure 2B).
LVEF and NT-proBNP were linearly correlated in the whole population (p = 0.002). Interestingly, only patients with coronary atherosclerosis and
inducible myocardial ischemia had significantly decreased LVEF values as compared with all the other patient groups (Figure 3).
Discussion
10
The present study examines the relative effects of coronary atherosclerotic burden and
inducible myocardial ischemia on circulating levels of hs-cTnT and NT-proBNP in
patients with stable CAD . The main findings of the present study can be summarized
as follows:
1. circulating levels of hs-cTnT are related with presence and extent of coronary
lesions as well as coronary plaque composition; in addition the global coronary
atherosclerotic burden, as assessed by CTA risk score, is a predictor of hs-cTnT
plasma levels independently of inducible myocardial ischemia;
2. circulating levels of NT-proBNP are mainly related with the presence of
functionally relevant coronary disease causing myocardial ischemia.
Cardiac troponins are the marker of choice for the detection of myocardial injury and
the diagnosis of myocardial infarction, as recommended by the most recent guidelines
(20-21). Over the past 10 years cTn assays have been improved in analytical
sensitivity and precision thereby allowing the measurement of cTn in nearly all
healthy subjects (22-23) and patients with stable CAD (5-6). In stable CAD
release of cTnT has been linked to the extent of coronary atherosclerosis (4-6) while
the relationship with transient inducible myocardial ischemia is debated (24-29).
In this study, an association of plasma hs-cTnT with several features of coronary
atherosclerosis as well as the presence of myocardial ischemia was observed.
However, only the global atherosclerotic burden, as assessed by CTA risk score, and
11
not myocardial ischemia, was an independent predictor of hs-cTnT levels at
multivariate analysis. Patients with coronary atherosclerosis showed significantly
higher levels of hs-cTnT compared with patients without, independently of the
presence of inducible myocardial ischemia (Figure 3).
The mechanisms of hs-cTnT elevation in patients with stable CAD, who had no
occurrence of acute events with myocyte necrosis, are not fully understood.
Consistently with the present findings, it has been hypothesized that at the site of
atherosclerotic lesions, dislodging and erosion processes could cause micro-
embolization of atherosclerotic and thrombotic material into the microcirculation (4,
30-31). Plaques more prone to erosion have a different composition than more stable
plaques. It has been very recently reported that chronic clinically silent rupture of non-
calcified plaque with subsequent microembolisation may be a potential source of
troponin elevation (32). These findings are in line with results from this study, in
which patients with higher coronary atherosclerotic burden and mixed plaques showed
higher levels of hs-cTnT than patients without.
The phenomenon of microembolization can cause myocardial damage and troponin
release. Mechanisms of progressive myocardial damage involve tumor necrosis factor
alpha (TNF-alpha) and nitric oxide (NO) (33-35) . It has been observed in an animal
model of coronary microembolization that an increase in TNF-alpha is associated with
modification of myofibrillar proteins, such as tropomyosin (36). TNF-alpha binds to
12
its receptors to activate a cascade of caspases leading to apoptosis (37-38).
Microembolization also causes excessive NO and oxidation (34). Excessive NO may
also trigger apoptotic pathways of cardiomyocytes (38). Importantly, in vitro studies
have demonstrated that, during the apoptotic process, caspase-3 activation results in
cleavage of cTn and subsequent release (4, 38-39). It remains to be established how
cardiomyocytes could release cTnT. Potential mechanisms beyond rupture of plasma
membrane have been suggested such as increased cellular wall permeability due to
myocardial stretch or ischemia and formation and active secretion of membranous
blebs from cardiac cells (24). Taking into account all these data, it is possible to
hypothesize that elevated hs-cTnT levels observed in patients with stable CAD may
be the result of microembolization activating the apoptotic program within cardiac
myocytes. This could explain why hs-cTnT levels are associated with the extent and
composition of atherosclerotic plaques in the present study. Whether this could be also
the basis of the association of hs-cTnT with cardiovascular mortality in patients with
stable CAD (5-6) remains to be demonstrated.
In patients with HF, elevation of NT-proBNP is proportional to the extent of
ventricular dysfunction (40). However elevation of this biomarker may be found in
patients without HF and without overt LV dysfunction. There are a few data
demonstrating the association of NT-proBNP circulating levels with coronary
atherosclerosis and myocardial ischemia in patients with stable CAD (41-43). It has
13
been found that NT-proBNP plasma levels were elevated in patients with obstructive
coronary artery lesions (defined as a diameter stenosis >70%) and proportional to the
number of affected vessels. Most importantly, experimental (44-45) studies have
provided evidence that myocardial ischemia may cause per se an increased expression
and secretion of natriuretic peptides by ventricular myocytes, triggering the release
and induction of de novo synthesis of BNP. In clinical studies (41, 43, 46-48)
measurement of plasma levels of NT-proBNP and BNP can distinguish patients with
and without inducible ischemia with a high degree of accuracy even after adjustment
for LV function (43). In this study, both coronary atherosclerotic burden and presence
of inducible myocardial ischemia were predictors of higher NT-proBNP plasma levels
in patients with stable CAD. However, at variance with hs-cTnT, only the presence of
inducible myocardial ischemia was an independent predictor of higher NT-proBNP.
Patients with obstructive coronary lesions and inducible ischemia had significantly
higher values of NT-proBNP than all the other patients (Figure 2). Moreover, NT-
proBNP levels were not associated with the characteristics of coronary plaques.
Therefore, it is conceivable that the elevation of NT-proBNP in this study reflects the
chronic and cumulative effects of repetitive myocardial ischemia due to obstructive
CAD. As a matter of fact, despite patients were enrolled after exclusion of subject with
LV systolic dysfunction (LVEF < 45%), LVEF and NT-proBNP were linearly
correlated in the whole population and lower LVEF was an independent predictor of
14
higher NT-proBNP values. Interestingly, only patients with obstructive coronary
disease and inducible myocardial ischemia had both significantly increased NT-
proBNP and signicantly decreased LVEF values as compared with all the other patient
groups (Figure 3). Increased release of BNP from the cardiac myocytes may be
consequent to the direct effects of repetitive ischemia on the cardiac myocytes
resulting in an increased gene expression (44-45) as well as a consequence of
subclinical ventricular dysfunction and mechanical myocardial stretching secondary
to myocardial stunning (49). Whichever the mechanism, our results underline the
relevance of circulating NT-proBNP as a marker of chronic ischemic coronary disease
and are in agreement with the known prognostic role of this biomarker in patients with
stable CAD (9-10).
A schematic representation of the proposed mechanisms explaining the increased
levels of hs-cTnT and NT-proBNP in patients with stable CAD is reported in Figure 4.
Conclusions
The present study provides evidence that circulating hs-cTnT and NT-proBNP levels,
even if in the normal range, may provide different and complementary information on
the presence and severity of CAD in patients with stable angina. Relative increase in
circulating hs-cTnT is a marker of the coronary atherosclerotic process being related
with the global atherosclerotic burden and with the type of atherosclerotic plaques. On
15
the other hand, relative increase in circulating NT-proBNP is mainly associated with
inducible myocardial ischemia due to more severe coronary lesions and expresses a
subclinical LV dysfunction possibly consequent to the chronic ischemic process.
According to these results, the two biomarkers may have a relevant clinical role in the
screening process of patients with stable angina. Further studies are needed to define
whether these biomarkers can improve the accuracy of clinical and bio-humoral
models used to predict the presence, severity of CAD and outcome in patients with
stable angina. In particular, the combined use of hs-cTnT and NT-proBNP may be a
powerful tool to stratify these subjects prior to further clinical investigation and to
target personalized treatment.
As a future perspective, more information should be obtained to extend our present
understanding of patho-physiological mechanisms explaining the effects of the
different patterns of atherosclerotic disease on cardiac structure and endocrine
function. Methodological improvements could help in this direction by providing more
specific methods to distinguish intact non-degraded protein chain or proteolytic
troponin degradation products (50) as well as different active peptide BNP forms
instead of inactive peptide NT-proBNP (51).
Acknowledgements
16
Roche Diagnostics International Ltd (Switzerland) kindly supplied all reagents and
calibrators used in the study for the measurement of hs-cTnT and NT-proBNP plasma
levels in the EVINCI population.
17
References
1. Valgimigli M, Biscaglia S. Stable angina pectoris. Curr Atheroscler Rep. 2014
Jul;16(7):422.
2. Task Force Members. 2013 ESC guidelines on the management of stable coronary
artery disease: The Task Force on the management of stable coronary artery
disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
3. American College of Cardiology Foundation Appropriate Use Criteria Task Force.
CCF/AHA/ASE/ASNC/ HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality
appropriate use criteria for the detection and risk assessment of stable ischemic
heart disease: a report of the American College of Cardiology Foundation
Appropriate Use Criteria Task Force, American Heart Association, American
Society of Echocardiography, American Society of Nuclear Cardiology, Heart
Failure Society of America, Heart Rhythm Society, Society for Cardiovascular
Angiography and Interventions, Society of Cardiovascular Computed
Tomography, Society for Cardiovascular Magnetic Resonance, and Society of
Thoracic Surgeons. J Am Coll Cardiol 2014;63:380-406.
4. Laufer EM, Mingels AM, Winkens MH, Joosen IA, Schellings MW, Leiner T,
Wildberger JE, Narula J, Van Dieijen-Visser MP, Hofstra L. The extent of
coronary atherosclerosis is associated with increasing circulating levels of high
18
sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1269-
75. doi: 10.1161/ATVBAHA.109.200394.
5. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA,
Tjora S, Domanski MJ, Gersh BJ, Rouleau JL, Pfeffer MA, Braunwald E;
Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE)
Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery
disease. N Engl J Med. 2009 Dec 24;361(26):2538-47.
6. Ndrepepa G, Braun S, Mehilli J, Birkmeier KA, Byrne RA, Ott I, Hösl K, Schulz
S, Fusaro M, Pache J, Hausleiter J, Laugwitz KL, Massberg S, Seyfarth M,
Schömig A, Kastrati A. Prognostic Value of Sensitive Troponin T in Patients with
Stable and Unstable Angina and Undetectable Conventional Troponin. Am Heart J
2011;161:68–75.
7. Clerico A, Giannoni A. Will high-sensitive troponin immunoassays lead to more
clarity or confusion in clinical practice? Clin Sci (Lond). 2010 Jun 2;119(5):203-5.
8. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third
universal definition of myocardial infarction. Eur Heart J 2012;33:2551–2567.
9. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-
B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
N Engl J Med. 2005 Feb 17;352(7):666-75.
19
10. Ndrepepa G, Braun S, Niemöller K, Mehilli J, von Beckerath N, von Beckerath O,
Vogt W, Schömig A, Kastrati A. Prognostic value of N-terminal pro-brain
natriuretic peptide in patients with chronic stable angina. Circulation. 2005 Oct
4;112(14):2102-7.
11. Del Ry S, Cabiati M, Clerico A. Natriuretic peptide system and the heart. Front
Horm Res. 2014;43:134-43.
12. Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, Pizzi MN,
Todiere G, Gimelli A, Schroeder S, Drosch T, Poddighe R, Casolo G,
Anagnostopoulos C, Pugliese F, Rouzet F, Le Guludec D, Cappelli F, Valente S,
Gensini GF, Zawaideh C, Capitanio S, Sambuceti G, Marsico F, Perrone Filardi P,
Fernández-Golfín C, Rincón LM, Graner FP, de Graaf MA, Fiechter M, Stehli J,
Gaemperli O, Reyes E, Nkomo S, Mäki M, Lorenzoni V, Turchetti G, Carpeggiani
C, Marinelli M, Puzzuoli S, Mangione M, Marcheschi P, Mariani F, Giannessi D,
Nekolla S, Lombardi M, Sicari R, Scholte AJ, Zamorano JL, Kaufmann PA,
Underwood SR, Knuuti J; EVINCI Study Investigators. Detection of significant
coronary artery disease by noninvasive anatomical and functional imaging. Circ
Cardiovasc Imaging. 2015 Mar;8(3).
13. Caselli C, Rovai D, Lorenzoni V, Carpeggiani C, Teresinska A, Aguade S, Todiere
G, Gimelli A, Schroeder S, Casolo G, Poddighe R, Pugliese F, Le Guludec D,
Valente S, Sambuceti G, Perrone-Filardi P, Del Ry S, Marinelli M, Nekolla S,
20
Pietila M, Lombardi M, Sicari R, Scholte A, Zamorano J, Kaufmann PA,
Underwood SR, Knuuti J, Giannessi D, Neglia D; EVINCI Study Investigators. A
New Integrated Clinical-Biohumoral Model to Predict Functionally Significant
Coronary Artery Disease in Patients With Chronic Chest Pain. Can J Cardiol. 2015
Jun;31(6):709-16.
14. Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, Giannessi
D, Bax JJ, Neglia D, Scholte AJ. HDL cholesterol, leptin and interleukin-6 predict
high risk coronary anatomy assessed by CT angiography in patients with stable
chest pain. Atherosclerosis. 2015 Jul;241(1):55-61.
15. Franzini M, Masotti S, Prontera C, Passino C, Clerico A. Clinical implications of a
recent adjustment to the high-sensitivity cardiac troponin T assay: some results.
Clin Chem Lab Med 2014; 52: E21-E23.
16. Prontera C, Zucchelli CG, Vittorini S, Storti S, Emdin M, Clerico A. Comparison
between analytical performances of polyclonal and monoclonal
electrochemiluminescence immunoassauys for NT-proBNP. Clin Chim Acta 2009;
400: 70-3
17. de Graaf MA, Broersen A, Ahmed W, Kitslaar PH, Dijkstra J, Kroft LJ, Delgado
V, Bax JJ, Reiber JH, Scholte AJ. Feasibility of an automated quantitative
computed tomography angiography-derived risk score for risk stratification of
21
patients with suspected coronary artery disease. Am J Cardiol. 2014;113(12):1947-
55.
18. Gaemperli O, Schepis T, Kalff V, Namdar M, Valenta I, Stefani L, Desbiolles L,
Leschka S, Husmann L, Alkadhi H, Kaufmann PA. Validation of a new cardiac
image fusion software for three-dimensional integration of myocardial perfusion
SPECT and stand-alone 64-slice CT angiography. Eur J Nucl Med Mol Imaging
2007;34:1097-106.
19. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK,
Pennell DJ, Rumberger JA, Ryan T, Verani MS; American Heart Association
Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging.
Standardized myocardial segmentation and nomenclature for tomographic imaging
of the heart. A statement for healthcare professionals from the Cardiac Imaging
Committee of the Council on Clinical Cardiology of the American Heart
Association. Circulation 2002;105:539-42.
20. Hamm CW1, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek
D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF,
Wijns W, Zahger D; ESC Committee for Practice Guidelines. ESC Committee for
Practice Guidelines. ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment elevation: the
Task Force for the management of acute coronary syndromes (ACS) in patients
22
presenting without persistent ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J. 2011 Dec;32(23):2999-3054.
21. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-
Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A,
Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice
Guidelines (CPG). ESC Committee for Practice Guidelines (CPG). ESC guidelines
for the diagnosis and treatment of acute and chronic heart failure 2008: the Task
Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the
European Society of Cardiology. Developed in collaboration with the Heart
Failure Association of the ESC (HFA) and endorsed by the European Society of
Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008 Oct;10(10):933-89.
22. Franzini M, Lorenzoni V, Masotti S, Prontera C, Chiappino D, Latta DD, Daves
M, Deluggi I, Zuin M, Ferrigno L, Mele A, Marcucci F, Caserta CA, Surace P,
Messineo A, Turchetti G, Passino C, Emdin M, Clerico A. The calculation of the
cardiac troponin T 99th percentile of the reference population is affected by age,
gender, and population selection: a multicenter study in Italy. Clin Chim Acta.
2015 Jan 1;438:376-81.
23. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac
troponin I measured by the high-sensitivity cardiac troponin I access prototype
23
assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol
2009;54:1165–72.
24. White HD. Pathobiology of troponin elevations: do elevations occur with
myocardial ischemia as well as necrosis? J Am Coll Cardiol. 2011 Jun
14;57(24):2406-8.
25. Turer AT, Addo TA, Martin JL, Sabatine MS, Lewis GD, Gerszten RE, Keeley
EC, Cigarroa JE, Lange RA, Hillis LD, de Lemos JA. Myocardial ischemia
induced by rapid atrial pacing causes troponin T release detectable by a highly
sensitive assay: insights from a coronary sinus sampling study. J Am Coll Cardiol.
2011 Jun 14;57(24):2398-405.
26. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of
acute changes in circulating troponin in the setting of transient stress test-induced
myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur
Heart J. 2009 Jan;30(2):162-9.
27. Kurz K, Giannitsis E, Zehelein J, Katus HA. Highly sensitive cardiac troponin T
values remain constant after brief exercise- or pharmacologic-induced reversible
myocardial ischemia. Clin Chem. 2008 Jul;54(7):1234-8.
28. Røysland R, Kravdal G, Høiseth AD, Nygård S, Badr P, Hagve TA, Omland T,
Røsjø H. Cardiac troponin T levels and exercise stress testing in patients with
24
suspected coronary artery disease: the Akershus Cardiac Examination (ACE) 1
study. Clin Sci (Lond). 2012 Jun;122(12):599-606.
29. Konishi M, Sugiyama S, Sugamura K, Nozaki T, Ohba K, Matsubara J, Sakamoto
K, Nagayoshi Y, Sumida H, Akiyama E, Matsuzawa Y, Sakamaki K, Morita S,
Kimura K, Umemura S, Ogawa H. Basal and ischemia-induced transcardiac
troponin release into the coronary circulation in patients with suspected coronary
artery disease. PLoS One. 2013;8(4):e60163.
30. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden
coronary death: a comprehensive morphological classification scheme for
atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75.
31. Heusch G, Schulz R, Haude M, Erbel R. Coronary microembolization. J Mol Cell
Cardiol. 2004 Jul;37(1):23-31.
32. Korosoglou G, Lehrke S, Mueller D, Hosch W, Kauczor HU, Humpert PM,
Giannitsis E, Katus HA. Determinants of troponin release in patients with stable
coronary artery disease: insights from CT angiography characteristics of
atherosclerotic plaque.Heart. 2011 May;97(10):823-31.
33. Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, Frede S,
Hartung T, Vinten-Johansen J, Youker KA, Entman ML, Erbel R, Heusch G.
Coronary microembolization: the role of TNF-alpha in contractile dysfunction. J
Mol Cell Cardiol. 2002 Jan;34(1):51-62.
25
34. Thielmann M, Dörge H, Martin C, Belosjorow S, Schwanke U, van De Sand A,
Konietzka I, Büchert A, Krüger A, Schulz R, Heusch G. Myocardial dysfunction
with coronary microembolization: signal transduction through a sequence of nitric
oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res. 2002 Apr
19;90(7):807-13.
35. Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, Heusch G.
Bidirectional role of tumor necrosis factor-alpha in coronary microembolization:
progressive contractile dysfunction versus delayed protection against infarction.
Circ Res. 2007 Jan 5;100(1):140-6.
36. Canton M, Skyschally A, Menabò R, Boengler K, Gres P, Schulz R, Haude M,
Erbel R, Di Lisa F, Heusch G. Oxidative modification of tropomyosin and
myocardial dysfunction following coronary microembolization. Eur Heart J. 2006
Apr;27(7):875-81. Epub 2006 Jan 24.
37. Chen QM, Tu VC. Apoptosis and heart failure: mechanisms and therapeutic
implications. Am J Cardiovasc Drugs. 2002;2(1):43-57.
38. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ.
Functional consequences of caspase activation in cardiac myocytes. Proc Natl
Acad Sci U S A. 2002 Apr 30;99(9):6252-6.
26
39. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U,
Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart
failure. N Engl J Med. 1996 Oct 17;335(16):1182-9.
40. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow
GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC,
Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam
F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of
Cardiology Foundation; American Heart Association Task Force on Practice
Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a
report of the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62:e147–
239.
41. Weber M1, Dill T, Arnold R, Rau M, Ekinci O, Müller KD, Berkovitsch A,
Mitrovic V, Hamm C. N-terminal B-type natriuretic peptide predicts extent of
coronary artery disease and ischemia in patients with stable angina pectoris Am
Heart J. 2004 Oct;148(4):612-20.
42. Peer A, Falkensammer G, Alber H, Kroiss A, Griesmacher A, Ulmer H, Pachinger
O, Mair J. Limited utilities of N-terminal pro B-type natriuretic peptide and other
newer risk markers compared with traditional risk factors for prediction of
27
significant angiographic lesions in stable coronary artery disease. Heart. 2009
Feb;95(4):297-303.
43. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. B-type
natriuretic peptide and ischemia in patients with stable coronary disease: data from
the Heart and Soul study. Circulation 2003;108:2987–92.
44. Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, Eckardt
KU, Warnecke C. Hypoxia, via stabilization of the hypoxia-inducible factor HIF-
1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide
induction. Biochem J. 2008 Jan 1;409(1):233-42.
45. Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, Jiménez W. Hypoxia
induces B-type natriuretic peptide release in cell lines derived from human
cardiomyocytes. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H550-5.
46. Yeo KT, Lee HK, Wong KC, Foote RS. Can exercise-induced changes in B-type
natriuretic peptides be used to detect cardiac ischemia? J Card Fail. 2005 Jun;11(5
Suppl):S59-64.
47. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M,
Hall C, McCabe CH, Braunwald E. Acute changes in circulating natriuretic
peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004 Nov
16;44(10):1988-95.
28
48. Nakamura T, Sakamoto K, Yamano T, et al. Increased plasma brain natriuretic
peptide level as a guide for silent myocardial ischemia in patients with non-
obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:1657–63.
49. Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of
myocardial viability.Circulation. 2008 Jan 1;117(1):103-14.
50. Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations
of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial
tissue renewal? Clin Chem Lab Med. 2009;47(10):1167-77.
51. Clerico A, Passino C, Franzini M, Emdin M. Cardiac biomarker testing in the
clinical laboratory: where do we stand? General overview of the methodology with
special emphasis on natriuretic peptides. Clin Chim Acta. 2015 Mar 30;443:17-24.
29
Figure Legends
Figure 1. Relation of hs-cTnT and NT-proBNP with extent and severity of CAD.
Box plots represent hs-cTnT and NT-proBNP levels stratified per CAD severity (A)
and number of plaques (B).
Figure 2. Effect of coronary atherosclerosis and inducible myocardial ischemia
on hs-cTnT and NT-proBNP plasma levels.
Circulating levels of hs-cTnT and NT-proBNP in patients subdivided according to: A)
the absence of both CAD and ischemia (“Normals” group), the presence of only CAD
(CAD), of only ischemia (Ischemia), and of both of them (CAD plus Ischemia) (A); B)
the presence of a perfusion defect in a territory subtended by a stenotic coronary artery
on CTA (matched), of all other combinations of pathologic findings (unmatched) at
hybrid imaging analysis.
Figure 3. Effect of coronary atherosclerosis and inducible myocardial ischemia
on LV function.
Figure 4. Schematic model illustrating the suggested mechanisms of hs-cTnT and
NT-proBNP increasing plasma levels in patients with stable angina.
At the site of the atherosclerotic lesions, dislodging and erosion processes could cause
micro-embolization of atherosclerotic and thrombotic material into the
microcirculation. This phenomenon can cause myocardial damage triggering the
30
apoptotic process with consequently release of hs-cTnT from cardiac myocytes into
peripheral circulation. Vice versa, increase in circulating NT-proBNP is mainly
associated with inducible myocardial ischemia due to more severe coronary lesions
and expresses a subclinical LV dysfunction possibly consequent to the chronic
ischemic process. These mechanisms could be the basis of the association of hs-cTnT
and NT-proBNP with cardiovascular mortality in patients with stable CAD.
31
Table 1. Baseline clinical and biohumoral characteristics.
Clinical variables
Low
hs cTnT
(n=188)
High
hs cTnT
(n=188)
P
value
Low
NT-proBNP
(n=188)
High
NT-proBNP
(n=188)
P
value
Demographics
Age, yr 57.7 ± 0.6 62.5 ± 0.6 <0.0001 57.4 ± 0.7 62.8 ± 0.6 <0.0001
Male sex 95 (42) 131 (58) 0.0001 128 (56.6) 98 (43.4) 0.0016
CV risk factors
Family history of CAD 70 (45.3) 58 (54.7) ns 70 (54.7) 58 (45.3) ns
Diabetes mellitus 30 (33.7) 59 (66.3) 0.0004 53 (59.5) 36 (40.5) 0.0392
Hypertension 101 (45.9) 124 (55.1) 0.0155 107 (47.6) 118 (52.4) ns
Hypercholesterolemia 116 (53) 103 (47) ns 111 (50.7) 108 (49.3) ns
Obesity 35 (44.9) 43 (55.1) ns 38 (48.7) 40 (51.3) ns
Smoking 48 (55.3) 42 (46.7) ns 49 (54.4) 41 (45.6) ns
LV Function
LVEF, % 60 [55-67] 60 [55-65] ns 62 [58.5-67] 60 [50-65] <0.0001
Medications
Beta-blockers 74 (49.3) 76 (50.7) ns 51 (34) 99 (66) <0.0001
Calcium antagonists 17 (38.6) 27 (61.4) ns 19 (43.2) 25 (56.8) ns
ARBs/ACE Inhibitors 60 (37.7) 99 (62.3) <0.0001 72 (42.3) 87 (54.7) ns
Diuretics 25 (39) 39 (61) ns 31 (48.4) 33 (51.6) ns
Nitrates 16 (43.2) 21 (56.8) ns 16 (43.2) 21 (50.8) ns
Anti-thrombotics 104 (46.4) 120 (53.6) ns 100 (44.6) 124 (55.4) 0.0117
Oral antidiabetics/Insulin 23 (31.5) 50 (68.5) 0.0004 40 (54.8) 33 (45.2) ns
Statins 99 (50.3) 98 (49.7) ns 93 (44.7) 104 (55.3) ns
Bio-humoral variables
Creatinine, mg/dL 0.82 [0.68-0.97] 0.86 [0.75-1.02] 0.0113 0.85 [0.72-1.00] 0.83 [0.73-0.98] ns
Glucose, mg/dL 101 [90.8-114] 105.0 [93-126] 0.0033 104 [102-120] 102 [92-115.3] ns
32
Total cholesterol, mg/dL 183 [147.3-220] 177[142.3-209.5] ns 185[1473.3-216] 171[142-214.8] ns
LDL cholesterol, mg/dL 103 [78-136] 99 [75-128] ns 107 [78-131.5] 96 [75-128.2] ns
HDL cholesterol, mg/dL 52 [41-65] 47 [39.3-58] 0.0087 49 [41-59] 50 [40-63] ns
Triglycerides, mg/dL 98 [70.3-147.5] 109 [77.3-156] 0.0440 113 [77.3-163] 98 [71.3-128.5] 0.0048
hs-CRP, mg/dL 0.13 [0.07-0.30] 0.19 [0.09-0.38] 0.0427 0.14 [0.07-0.36] 0.18 [0.09-0.34] ns
CK-MB, mg/dL 1.4 [1.0-2.1] 1.9 [1.3-2.9] <0.0001 1.5 [1.0-2.4] 1.7 [1.2-2.5] ns
hs-cTnT, ng/L 4.2 [3.0-5.2] 9.09 [7.3-12.6] <0.0001 5.67 [4.0-8.3] 6.75 [4.5-9.6] 0.0122
NT-proBNP, ng/L 55.3[28.05-106.3] 68.0 [36.5-168.3] <0.0001 31.2 [16.1-49.1] 132.6[87.2-206.4] <0.0001
Continuous variables are presented as mean ± standard error or median [25-75 percentile], categorical variables as absolute N and (%). ARB = Angiotensin Receptor Blockers; ACE = Angiotensin Converting Enzyme.
33
Table 2. Coronary imaging and inducible ischemia.
Low
hs cTnT
(n=188)
High
hs cTnT
(n=188)
P
value
Low
NT-proBNP
(n=188)
High
NT-proBNP
(n=188)
P
value
Coronary anatomy
Normals 80 (71.4%) 32 (28.6%)
<0.0001
67 (59.8%) 45 (40.2%)
0.0004
Patients with non-obstructive
CAD (<50%)65 (46.1%) 76 (53.9%) 77 (54.6%) 64 (45.4%)
Patients with obstructive
CAD (≥50%)43 (35%) 80 (65%) 44 (35.8%) 79 (64.2%)
Coronary plaques
Patients with calcified plaque 57 (41.9%) 79 (58.1%) 0.0182 66 (49.1%) 70 (50.1%) ns
Patients with mixed plaque 87 (39.2%) 135 (60.8%) <0.0001 103 (46.4%) 119 (53.6%) ns
Patients with non-calcified plaque 47 (44.3%) 59 (55.7%) ns 52 (49.1%) 54 (50.9%) ns
N. of calcified plaques 0.7 ± 0.12 1 ± 0.13 ns 0.9 ± 0.1 0.8 ± 0.1 ns
N. of mixed plaques 1.7 ± 0.19 3.3 ± 0.25 <0.0001 2.2 ± 0.22 2.8 ± 0.25 ns
N. of non-calcified plaques 0.4 ± 0.06 0.5 ± 0.07 ns 0.4 ± 0.06 0.5 ± 0.07 ns
Risk scores
CTA risk score 4.0 [0.0-15.0] 12.9 [5.6-23.1] <0.0001 7.2 [0.0-16.6] 11.8 [1.7-22.3] 0.0084
CAC score (n= 297) 6 [0-127] 78 [6-423] <0.0001 31 [0-202] 46 [0-273] ns
Myocardial ischemia
Patients with inducible ischemia
(any modality)37 (37.7%) 61 (62.3%) 0.0046 34 (34.7%) 64 (65.3%) 0.0004
Patients with inducible ischemia
(MPI, n=298)33 (37.1%) 56 (62.9%) 0.0209 29 (32.6%) 60 (67.4%) 0.0003
SDS at MPI (n=298) 2.76 ± 0.57 4.10 ± 0.65 0.0274 1.79 ± 0.39 5.06 ± 0.74 <0.0001
Continuous variables are presented as mean ± standard error or median [25-75 percentile], categorical variables as absolute N and (%).
34
Table 3. Predictive factors of hs cTnT and NT-proBNP plasma levels at
multivariate analyses.
Variables hs cTnT * NT-proBNP **
Coefficient (SE) P Coefficient (SE) P
Age 0.011 (0.003) 0.0016 0.036 (0.007) <0.0001
Sex 0.278 (0.057) <0.0001 - 0.391 (0.109) 0.0004
LVEF --- --- - 0.993 (0.349) 0.0047
CTA Risk Score 0.060 (0.023) 0.0089 --- ---
Presence of Ischemia --- --- 0.384 (0.120) 0.0015
* adjusted for medications significantly associated with hs cTnT at univariate analysis, including ACE inhibitors/ARBs and insulin/oral anti-diabetics.** adjusted for medications significantly associated with NT-proBNP at univariate analysis, including beta-blockers, ACE inhibitors/ARBs, anti-thrombotics, and statins. ARB = Angiotensin Receptor Blockers; ACE = Angiotensin Converting Enzyme.
35